Hypothesis

ICAM-1 enrichment at tricellular endothelial junctions acts as a scaffold that recruits and activates the protein tyrosine phosphatase PTP1B. Activated PTP1B dephosphorylates eNOS at Thr495, shifting the enzyme from a coupled, NO‑producing state to an uncoupled, superoxide‑generating mode. The resulting ROS burst reinforces NF‑κB signaling, further increasing ICAM-1 transcription and SASP factor secretion (IL-6, IL-8). This creates a self‑propagating circuit where ICAM-1‑PTP1B‑eNOS uncoupling amplifies oxidative stress and senescence in the originating cell and, through paracrine ROS and vesicle‑mediated SASP, induces the same phenotype in neighboring endothelium.

Testable Predictions

1. PTP1B localization – In senescent human aortic endothelial cells (HAECs), PTP1B will co‑localize with ICAM-1 at tricellular junctions, detectable by proximity ligation assay (PLA) and super‑resolution microscopy.
2. Phosphatase activity – Junctional PTP1B activity will be elevated in senescent versus proliferating HAECs, and its inhibition (with siRNA, CRISPRi, or the small‑molecule inhibitor trodusquemine) will increase eNOS Thr495 phosphorylation and restore NO production (measured by DAF‑FM fluorescence) while reducing superoxide (hydroethidine assay).
3. ICAM-1 dependence – Blocking ICAM-1 clustering (using a function‑blocking antibody that prevents tricellular junction binding or siRNA against angulin-1, a tricellular junction protein) will diminish junctional PTP1B recruitment, attenuate eNOS uncoupling, and lower SASP secretion.
4. Paracrine senescence – Conditioned medium from senescent HAECs will induce eNOS uncoupling and ICAM-1 upregulation in naive endothelial cells; this effect will be abolished when donor cells are pre‑treated with PTP1B inhibitor or when the medium is depleted of extracellular vesicles (exosome‑free supernatant).
5. In vivo relevance – Endothelial‑specific PTP1B knockout mice (Tie2‑Cre; Ptpn1^fl/fl) subjected to partial carotid ligation or high‑fat diet will exhibit reduced eNOS superoxide production, lower ICAM-1 junctional clustering, decreased plasma IL-6/IL-8, and attenuated atherosclerotic lesion formation compared with littermate controls.

Experimental Approach

• Cell culture: HAECs induced to senescence by repeated passaging or TNF‑α (10 ng/mL, 5 days). Validate senescence via SA‑β‑gal, p16^INK4a, and p21^Cip1 expression.
• Biochemical assays: eNOS coupling assessed by NADPH‑oxidase‑dependent superoxide vs NO production; Western blot for phospho‑Thr495 eNOS; ELISA for IL-6, IL-8.
• Immunofluorescence/STORM: Co‑staining for ICAM-1, PTP1B, and junctional markers (VE‑cadherin, angulin-1); quantify Pearson’s coefficient and cluster size at tricellular contacts.
• Functional assays: Leukocyte adhesion (THP-1 cells under flow), transendothelial electrical resistance (TEER) for barrier integrity, and monocyte transmigration.
• In vivo: Use ApoE‑/‑ background to accelerate atherosclerosis; lesion area quantified by Oil‑Red‑O staining; immunofluorescence for eNOS uncoupling (3‑nitrotyrosine) and ICAM-1 in aortic sections.

Falsifiability

If PTP1B inhibition or disruption of ICAM-1 junctional clustering fails to restore eNOS coupling, reduce ROS, or lower SASP in senescent endothelial cells, or if endothelial‑specific PTP1B knockout does not attenuate atherosclerosis‑associated inflammation, the hypothesis would be refuted. Conversely, confirming the predicted mechanistic links would support a novel therapeutic node that uncouples the ROS‑ICAM-1‑SASP axis without globally suppressing ICAM-1’s potential pro‑resolution functions.